Advertisement
U.S. markets closed

Gossamer Bio, Inc. (GOSS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.2200-0.0400 (-3.17%)
At close: 04:00PM EST
1.2388 +0.02 (+1.54%)
After hours: 05:39PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close1.2600
Open1.2800
Bid1.1900 x 900
Ask1.2000 x 1300
Day's Range1.1400 - 1.3000
52 Week Range0.4530 - 1.9600
Volume2,655,937
Avg. Volume1,367,231
Market Cap274.999M
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-1.6000
Earnings DateMar 15, 2024 - Mar 19, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.09
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GOSS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Gossamer Bio, Inc.
    Daily – Vickers Top Buyers & Sellers for 07/18/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • InvestorPlace

    7 Micro-Cap Stocks That Could Majorly Surprise Investors

    Practically by default, your typical financial advisor will steer you clear of micro-cap stock surprises in favor of large-capitalization enterprises. Yes, the blue chips are reliable and dependable but this underlying predictability often comes at a cost: usually, you’re not going to get rich off of them. On the other hand, finding micro-cap stock surprises is like picking up the next Tom Brady in the final round of the NFL Draft. More often than not, your draft picks will end up being largely

  • Business Wire

    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, January 08, 2024--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective January 5, 2024, to two new non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 212,500 shares of the Company’s com

  • Business Wire

    Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

    SAN DIEGO, December 13, 2023--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it will host a public conference call and webcast for investors and analysts on Monday, December 18, 2023 at 8:30 am ET to discuss the latest seralutinib clinical data from the ongoing TORREY Phase 2 Open-Label Extension Study in PAH patients. Ser